fuzuloparib + bevacizumab

The combination of fuzuloparib and bevacizumab is being investigated as a treatment option for various cancers, particularly ovarian cancer. Fuzuloparib is a PARP (poly ADP-ribose polymerase) inhibitor that works by impeding DNA repair mechanisms in cancer cells, leading to their death[3][4]. Bevacizumab is an anti-angiogenic agent that targets VEGF (vascular endothelial growth factor) to inhibit the formation of new blood vessels that supply tumors. ## Clinical Development This combination is currently being studied in clinical trials, particularly for ovarian cancer. One notable study mentioned in the search results is the CHANGCHUN trial, which is investigating adebrelimab (a PD-L1 inhibitor) plus chemotherapy and bevacizumab as induction therapy, followed by maintenance therapy with adebrelimab plus fuzuloparib and bevacizumab in platinum-sensitive relapsed ovarian cancer[5]. The rationale for combining PARP inhibitors with anti-angiogenic agents like bevacizumab is supported by previous successful combinations, such as olaparib plus bevacizumab. The FDA approved olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers in May 2020[7]. This approval was based on the PAOLA-1 trial, which demonstrated the efficacy of this combination against an established maintenance therapy[6]. ## Dosing Information While specific dosing information for fuzuloparib + bevacizumab is not explicitly provided in the search results, we can note that in similar combinations: - Fuzuloparib is typically administered at 100 mg orally twice daily in clinical trials[3][4][5] - Bevacizumab is typically administered intravenously every 3 weeks for a total duration of up to 15 months (as seen with olaparib combinations)[6] ## Mechanism of Action The combination leverages complementary mechanisms: 1. Fuzuloparib (PARP inhibitor): Halts the DNA repair mechanism for single-stranded breaks, resulting in DNA damage accumulation and cancer cell death[4] 2. Bevacizumab (anti-angiogenic agent): Inhibits the formation of new blood vessels that supply tumors by targeting VEGF This combination approach is part of a broader trend in oncology to combine PARP inhibitors with other therapeutic agents to enhance efficacy, particularly in patients with specific genetic profiles such as HRD (homologous recombination deficiency) positivity.